bevacizumab + cyclophosphamide + docetaxel + epirubicin + fluorouracil

This is a combination chemotherapy regimen consisting of five agents—bevacizumab, cyclophosphamide, docetaxel, epirubicin, and fluorouracil—used primarily in the neoadjuvant treatment of HER2-negative early or inflammatory breast cancer. - **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis and reducing tumor blood supply. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA to prevent cell division. - **Docetaxel** is a taxane that stabilizes microtubules and inhibits mitosis. - **Epirubicin** is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage. - **Fluorouracil (5-FU)** is an antimetabolite that interferes with DNA synthesis by inhibiting thymidylate synthase. This combination has been studied in phase 2 and 3 clinical trials for its efficacy in increasing pathological complete response rates when used as neoadjuvant therapy for HER2-negative breast cancer[1][2][3]. The addition of bevacizumab to standard chemotherapy regimens has shown increased pathological complete response but with higher rates of certain toxicities such as neutropenia[1][2].